Literature DB >> 1473990

Inhibition of acyl-CoA: cholesterol acyltransferase activity by cyclodepsipeptide antibiotics.

H Tomoda1, X H Huang, J Cao, H Nishida, R Nagao, S Okuda, H Tanaka, S Omura, H Arai, K Inoue.   

Abstract

The effect was studied of the fungal cyclodepsipeptide antibiotics beauvericin and seven distinct enniatins on acyl-CoA: cholesterol acyltransferase (ACAT) activity. In an enzyme assay using rat liver microsomes, all the compounds were found to inhibit ACAT activity. The drug concentration that caused 50% inhibition (IC50 value) of the enzyme activity was determined to be 3.0 microM for beauvericin, indicating that the compound is one of the most potent ACAT inhibitors of microbial origin. Enniatins exhibited much higher IC50 values of 22 to 110 microM. More hydrophobic enniatins showed more potent inhibitory activity. Furthermore, the ACAT inhibitory activity was evaluated as inhibition of cholesteryl ester formation in a cell assay using J774 macrophages. Calculation of the ratio, CD50 value (the drug concentration causing 50% cell damage)/IC50 value of cholesteryl ester formation, indicated that beauvericin shows the highest specificity. These data indicate that beauvericin is one of the most potent and specific ACAT inhibitors of microbial origin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473990     DOI: 10.7164/antibiotics.45.1626

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  24 in total

1.  A new enniatin antibiotic from the endophyte Fusarium tricinctum Corda.

Authors:  Ahmed M Zaher; Makboul A Makboul; Ahmad M Moharram; Babu L Tekwani; Angela I Calderón
Journal:  J Antibiot (Tokyo)       Date:  2014-10-15       Impact factor: 2.649

Review 2.  Revisiting the enniatins: a review of their isolation, biosynthesis, structure determination and biological activities.

Authors:  Arlene A Sy-Cordero; Cedric J Pearce; Nicholas H Oberlies
Journal:  J Antibiot (Tokyo)       Date:  2012-09-19       Impact factor: 2.649

3.  The effect of the Fusarium metabolite beauvericin on electromechanical and -physiological properties in isolated smooth and heart muscle preparations of guinea pigs.

Authors:  R Lemmens-Gruber; B Rachoy; E Steininger; K Kouri; P Saleh; R Krska; R Josephs; M Lemmens
Journal:  Mycopathologia       Date:  2000-01       Impact factor: 2.574

4.  Occurrence of beauvericin and enniatins in wheat affected by Fusarium avenaceum head blight.

Authors:  A Logrieco; A Rizzo; R Ferracane; A Ritieni
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

5.  Search for cell motility and angiogenesis inhibitors with potential anticancer activity: beauvericin and other constituents of two endophytic strains of Fusarium oxysporum.

Authors:  Jixun Zhan; Anna M Burns; Manping X Liu; Stanley H Faeth; A A Leslie Gunatilaka
Journal:  J Nat Prod       Date:  2007-02-08       Impact factor: 4.050

6.  Beauvericin production by Fusarium species.

Authors:  A Logrieco; A Moretti; G Castella; M Kostecki; P Golinski; A Ritieni; J Chelkowski
Journal:  Appl Environ Microbiol       Date:  1998-08       Impact factor: 4.792

7.  Production of beauvericin byFusarium proliferatum from maize in Italy.

Authors:  A Moretti; A Logrieco; A Bottalico; A Ritieni; G Randazzo
Journal:  Mycotoxin Res       Date:  1994-09       Impact factor: 3.833

8.  Effect ofTrichoderma species on growth of Fusariumproliferatiom and production of fumonisins, fusaproliferin and beauvericin.

Authors:  F Rojo; M Ferez; M Reynoso; A Torres; S Chulze
Journal:  Mycotoxin Res       Date:  2007-12       Impact factor: 3.833

9.  Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages.

Authors:  Ichiji Namatame; Hiroshi Tomoda; Shun Ishibashi; Satoshi Omura
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-12       Impact factor: 11.205

10.  High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections.

Authors:  Lixin Zhang; Kezhi Yan; Yu Zhang; Ren Huang; Jiang Bian; Chuansen Zheng; Haixiang Sun; Zhihui Chen; Nuo Sun; Rong An; Fangui Min; Weibo Zhao; Ying Zhuo; Jianlan You; Yongjie Song; Zhenyan Yu; Zhiheng Liu; Keqian Yang; Hong Gao; Huanqin Dai; Xiaoli Zhang; Jian Wang; Chengzhang Fu; Gang Pei; Jintao Liu; Si Zhang; Michael Goodfellow; Yuanying Jiang; Jun Kuai; Guochun Zhou; Xiaoping Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.